- Home
- OLOX vs BOLT Comparison
OLOX vs BOLT Comparison
Compare OLOX & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OLOX | BOLT |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 7.3M |
| IPO Year | 2011 | 2021 |
Fundamental Metrics
Financial Performance| Metric | OLOX | BOLT |
|---|---|---|
| Price | $2.70 | $3.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $34.00 |
| AVG Volume (30 Days) | ★ 38.0K | 21.3K |
| Earning Date | 06-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,952,578.00 | ★ $7,695,000.00 |
| Revenue This Year | $1,628.82 | N/A |
| Revenue Next Year | N/A | $133.33 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 0.07 |
| 52 Week Low | $0.45 | $3.13 |
| 52 Week High | $11.40 | $7.20 |
Technical Indicators
Market Signals| Indicator | OLOX | BOLT |
|---|---|---|
| Relative Strength Index (RSI) | 26.43 | 34.35 |
| Support Level | $0.58 | N/A |
| Resistance Level | $6.03 | $4.46 |
| Average True Range (ATR) | 0.49 | 0.22 |
| MACD | -0.17 | -0.06 |
| Stochastic Oscillator | 3.83 | 20.59 |
Price Performance
Historical ComparisonAbout OLOX Olenox Industries Inc. Common Stock
Olenox Industries Inc is an industrial holding company focused on acquiring, operating, and scaling businesses that provide engineered solutions across industrial, energy, and infrastructure markets. Through its subsidiaries, it delivers high-quality modular and containerized systems designed for rapid deployment and long-term performance.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.